Gilead reported 2025 revenue of $29.44 billion and Q1 2026 revenue of $6.96 billion. The thesis turns on whether HIV durability and cash generation can keep funding oncology, inflammation and pipeline expansion while patent, clinical and debt risks stay controlled.
The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.
